Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Cellavision - Not yet out of the doldrums

CellaVision

Redeye’s view on the Q1 report. The trend continues to be weak as was indicated in the earlier profit warning. The challenges continue to affect the company negatively. While some of them seem to be of a short-term nature, it means that we further lower our expectations. With the deviation from our expectations and continued uncertainty in the short to medium-term we have adjusted our estimates for 2023e. With these changes, we decrease our Base case to SEK 220 (280) and fair value range to SEK 155 – 380 (170 – 435) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Cellavision - Not yet out of the doldrums

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.